Examkin

Question

Difficulty: MediumPharmacologic Interventions

A 74-year-old woman presents to her primary care clinic to discuss progressive right knee pain that has been worsening over the past 6 months. She describes the pain as a deep, dull ache that worsens when climbing stairs and improves with rest. She experiences approximately 15 minutes of stiffness in the right knee upon waking in the morning. Her medical history includes hypertension, type 2 diabetes mellitus, stage 4 chronic kidney disease (baseline creatinine 2.4 mg/dL), and a remote history of a bleeding gastric ulcer that required endoscopic intervention. Her current medications are amlodipine, insulin glargine, and acetaminophen 1,000 mg three times daily. She reports that the acetaminophen no longer provides adequate pain relief. Vital signs are within normal limits. Physical examination reveals bony enlargement of the right knee with palpable crepitus during active range of motion. There is no significant warmth, erythema, or joint effusion. A recent radiograph of the right knee shows asymmetric joint space narrowing and subchondral sclerosis.

Which of the following is the most appropriate next step in the pharmacologic management of this patient's knee pain?

  1. A
    Oral celecoxib
  2. Topical diclofenacAnswer
  3. C
    Oral ibuprofen
  4. D
    Oral duloxetine
  5. E
    Oral prednisone

Answer

Topical diclofenac is the most appropriate intervention because it provides effective localized analgesia for knee osteoarthritis while avoiding the systemic renal and gastrointestinal risks associated with oral agents.
The correct answer is topical diclofenac. This patient has osteoarthritis of the knee that is no longer controlled with acetaminophen. According to current guidelines, topical nonsteroidal anti-inflammatory drugs (NSAIDs) are strongly recommended as a first-line pharmacologic therapy for knee osteoarthritis. Topical NSAIDs like diclofenac provide comparable local pain relief to oral NSAIDs but have minimal systemic absorption. This is particularly advantageous for this patient, who has severe comorbidities—specifically stage 4 chronic kidney disease and a history of a bleeding gastric ulcer—that make oral NSAIDs highly contraindicated. Topical diclofenac safely avoids the risks of renal function deterioration and gastrointestinal bleeding.

Step-by-Step Solution

1
Identify the primary diagnosis and reason for modifying therapy.
The patient has symptomatic knee osteoarthritis that is refractory to maximum-dose acetaminophen.
Establishing the baseline condition and treatment failure is necessary to advance the management algorithm.
2
Analyze the patient's comorbidities to identify absolute and relative contraindications.
The patient has stage 4 chronic kidney disease, a history of a bleeding gastric ulcer, and type 2 diabetes mellitus.
Comorbidities dictate which standard osteoarthritis therapies must be avoided to prevent severe iatrogenic complications.
3
Select the most appropriate analgesic that avoids systemic toxicity.
Topical diclofenac provides effective local pain relief with minimal systemic absorption, safely bypassing both renal and gastrointestinal risks.
Oral NSAIDs and duloxetine are contraindicated due to the severe renal impairment, and systemic NSAIDs pose an unacceptable risk of recurrent gastrointestinal bleeding.

Key Concept

Topical NSAIDs are the preferred first-line pharmacologic therapy for localized osteoarthritis (e.g., knee) in patients with significant comorbidities, such as severe chronic kidney disease or a high risk of gastrointestinal bleeding.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic